GILEAD PRESENTS ADDITIONAL DATA ON INVESTIGATIONAL ANTIVIRAL REMDESIVIR FOR THE TREATMENT OF COVID-19 
 
GILEAD SCIENCES INC - REMDESIVIR WAS ASSOCIATED WITH AN IMPROVEMENT IN CLINICAL RECOVERY AND A 62 PERCENT REDUCTION IN  RISK OF MORTALITY

$SPY #stocks #COVID $GILD